Circulation problems
Education on Circulation problems and Alpha-1 Antitrypsin research from the Mark Egly Foundation, with patent claims clearly labeled as hypothesis.
Research hypothesis, not medical advice
The connections described on this page come from Mark Egly's patent filing and ongoing research. They are not established medical facts. Always work with your physician for diagnosis and treatment.
Research hypothesis. The connection between Circulation problems and Alpha-1 Antitrypsin is described in Mark Egly's 2020 patent filing. This is not established medical fact and is not medical advice. Always talk with your doctor about your own health.
What is Circulation problems?
Circulation problems is a health condition discussed in Mark Egly's research on Alpha-1 Antitrypsin. Cardiovascular conditions affect the heart and blood vessels. The patent discusses oxidative stress, neutrophils, and AAT in vascular disease.
What Mark Egly's patent discusses
Raynaud's disease causes some areas of the body, often fingers or toes, to feel numb and cold in response to cold temperatures or stress. In Raynaud's disease, smaller arteries that supply blood to the skin narrow, limiting blood circulation to affected areas. Due to the link between AATD and Raynaud's disease and other circulation problems, in one embodiment AAT may be used to treat, control, or prevent circulation problems in patients, either with or without known AATD. A diagnosis of circulation problems may prompt a medical provider to test a patient for AATD. Alternatively, a patient diagnosed with circulation problems may seek genetic testing for AATD through an independent genetic testing company such as 23andMe or geneology.com, a pharmaceutical company supplied test kit or other private methods available. A method for treating a patient suffering from circulation problems with AAT begins with the step of determining if the patient is AAT deficient or has lower AAT levels without being AATD. Determining if the patient is AAT deficient or has lower AAT levels without being AATD proceeds as previously described in this disclosure in the section entitled "Determining if a pat…
How this may relate to Alpha-1
Mark Egly's patent proposes that when the body has too little working Alpha-1 Antitrypsin, or when neutrophils release too much neutrophil elastase, inflammation and tissue damage may worsen. For Circulation problems, the patent suggests that testing for AATD or low circulating AAT could help guide care. This is a research hypothesis, not a proven treatment path for everyone with this condition.
What you can do
If you or a family member lives with Circulation problems, consider learning about Alpha-1 Antitrypsin Deficiency and discussing AAT testing with your healthcare team. The Mark Egly Foundation offers education and community support: